Abstract:To ascertain if ras association domain family 1 (RASSF1) expression in esophageal squamous cell carcinoma (ESCC) can predict response to radiotherapy. The expression of RASSF1 was measured by immunohistochemical staining prospectively in 76 patients with ESCC who underwent radiotherapy between July 2008 and December 2011. The association between RASSF1 expression and clinicopathological variables and treatment response was assessed by the χ(2) test. The Kaplan-Meier curves were used to estimate probabilities of overall survival (OS) and progression-free survival (PFS). Cox proportional hazards regression model was used to independent predictors. P<0.05 was considered significant. Patients were followed-up for median months 18 (range: 4-61). Positive expression of RASSF1 manifested as brown staining in the cytoplasm or cell membranes, and significantly decreased in 46 of 76 (60.5%) of ESCC tissues compared with the matched normal tissues 95.0% (1/20) (P=0.003). Positive RASSF1 expression displayed a significant correlation with lower clinical stage (P=0.035), a better response to RT (P=0.001), and improved PFS (P=0.000) and OS (P=0.000). Multivariate analyses revealed that RASSF1-positive expression (Hazard ratio: 3.387, 95% confidence interval: 1.964-5.841, P=0.000) and complete response (Hazard ratio: 4.741, 95% confidence interval: 2.683-8.378, P=0.000) were significant prognostic factors. Therefore, RASSF1positive expression is involved in the sensitization of ESCC to radiotherapy and the prognosis of patients with ESCC.

Association of RASSF 1 expression with radiosensitivity / prognosis in esophageal squamous cell carcinoma